SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to a recently announced $9.7 billion AI cloud services deal with Microsoft, which includes access to NVIDIA GPUs and a 20% prepayment. The community is highly bullish, discussing potential price targets and the significance of this deal in establishing IREN as a major player in AI infrastructure. Some investors believe that AI revenue will soon drive the stock, decoupling it from Bitcoin's volatility.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as the community discusses its potential for growth, particularly regarding its QNX technology and partnerships with major tech companies. Some investors believe the current stock price undervalues the company's assets and future prospects, while others point to potential market manipulation and short-selling tactics affecting the stock's performance. The potential impact of government support and expansion in Asian markets are also being closely watched.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp sell-off possibly linked to news of a lawsuit against a former FDA official, which is creating uncertainty around the stock. The community is discussing the implications of this news, potential manipulation, and the company's upcoming earnings report. Some investors speculate about a buyout or partnership, while others express concern about the company's leadership and its impact on the stock's performance.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the tokenization of Satoshi Nakamoto, viewing it as more than just a meme, but as a representation of crypto culture and financial freedom. Discussions highlight the token's potential to become a significant asset, drawing parallels to Bitcoin's cultural impact and long-term value. The community emphasizes the narrative's timelessness and the ongoing initiatives surrounding the token.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending as investors discuss its recent $5.5 billion lease agreement with Amazon Web Services for AI workloads, a move that could significantly expand its business model. Community members are analyzing the deal's implications, including its potential impact on revenue and the company's transition towards AI infrastructure. Some traders are also eyeing upcoming earnings, anticipating further updates on the company's growth and strategy.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant stock movement following an unexpected shift in the FDA's stance on data requirements for its Huntington's disease therapy, AMT-130. The community is actively discussing the potential implications of this regulatory setback, with some speculating about a possible reversal of the decision or a buyout, while others assess the impact on the broader biotech sector. Discussions include the company's financial strategies, the possibility of a dead cat bounce, and the overall volatility and risk associated with biotech investments.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about whether this is a healthy correction or the start of a bear market, with some traders eyeing key support levels. Community members are weighing in with varied opinions, with some citing the 4-year cycle theory and others pointing to potential manipulation by large players. Discussions also include the impact of macro factors like government shutdowns and potential connections to AI and robotics investments.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is gaining attention as traders discuss its potential for a significant price movement, drawing comparisons to other low-float stocks that have experienced substantial short squeezes. Community members are actively watching the stock, citing its low float and speculating about news catalysts. Some believe a coordinated effort from retail investors could lead to a squeeze comparable to previous high-profile situations.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending following positive Phase 1 trial results for TERN-701 in chronic myeloid leukemia, with William Blair upgrading the stock to Outperform. The community is weighing the potential for a short squeeze and longer-term revenue prospects against concerns of a possible capital raise. Some investors are also comparing TERN to other companies in the obesity treatment space, questioning its transparency and market capitalization relative to its peers.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending amid discussions about potential dip-buying opportunities and revised price targets, with some analysts suggesting a bullish outlook. Community members are actively debating market manipulation and possible shakeouts before a potential run to all-time highs. Broader market factors, such as the potential impact of institutional investment and regulatory clarity, are also influencing the conversation.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apollomics shares fell 16% after-hours on Wednesday, even as the company said Nasdaq confirmed it remains in compliance with continued listing requirements, canceling a delisting appeal hearing.&nbsp;Trading in the company’s shares and warrants was halted on Sept. 17 for additional information.Reversal Of Wind-Up PlansThe update came as Apollomics continues to stabilize operations following financial challenges that nearly led to its shutdown. In August, the company announced plans to discontinue all clinical trial activities and wind up its business due to funding shortages.&nbsp;The company later reversed those plans in early September after receiving $4.1 million in PIPE investments and appointing a new management team led by CEO Hung-wen Chen, COO Yi-kuei Chen, and CFO Peter Lin.Focus On Late-Stage Oncology PipelineWith new funding and leadership, Apollomics said it is continuing its global Phase 2 SPARTA clinical trial for its lead drug candidate APL-101, a selective c-Met inhibitor for non-small cell lung cancer and other tumors with c-Met alterations.&nbsp;Apollomics said its lead cancer drug APL-101 has delivered encouraging results in more than 280 patients and remains at the center of its cancer research plans.The company added that its clinical trial partners have all been paid, and work is continuing without interruption. It has also implemented a 12-month plan to maintain its drug pipeline's momentum and ensure&nbsp;the company's financial stability during the next phase of development.Global Expansion PlansApollomics said it plans to leverage its existing China approvals for APL-101 in MET-amplified lung cancer and glioblastoma as a springboard for regulatory filings in Southeast Asia, the Middle East and other emerging markets.The company said it now has 12 employees and expects to have 15 employees by the end of October 2025. The company also expects to shift more roles from China to the U.S. and Taiwan to strengthen operations and ensure that its late-stage cancer drug programs remain on track.Stocktwits Traders Stay Upbeat Despite VolatilityOn Stocktwits, retail sentiment for Apollomics was ‘extremely bullish’ amid a 329% message volume.One user noted that the stock was in a very good position after being halted during the recent market pivot, while another highlighted the ongoing volatility in Apollomics shares.<stembedurl>https://stocktwits.com/Love_To_Learn/message/632496720</stembedurl><stembedurl>https://stocktwits.com/topstockalerts/message/632436028</stembedurl><a href="https://stocktwits.com/symbol/APLM">Apollomics’ stock</a> has doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Apollomics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Apollomics Stock Nosedived 16% After-Hours Today

The stock fell after-hours even after Nasdaq confirmed the biotech had regained compliance with listing standards.

Equity

Why Is Penny Stock Apollomics Trading Higher On Tuesday?

Apollomics shares soared after revealing promising Phase 2 SPARTA trial data for vebreltinib in non-CNS MET fusion solid tumors, showing a 43% ORR with notable responses in metastatic NSCLC...

Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CalciMedica (CALC Research Report), Apollomics (AP...

Apollomics price target lowered by $12 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript...

Apollomics reports FY23 EPS ($2.32) vs ($8.44) last year

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China...

Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 121.7% in February

Apollomics, Inc. (NASDAQ:APLM  Get Free Report) was the recipient of a large increase in short interest in February. As of February 29th, there was short interest totalling 43,900 shares, an...

Apollomics appoints Plunkett as CFO

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

Apollomics Inc - Ordinary Shares - Class A

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

APLM
Apollomics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest APLM News

APLMApollomics Inc - Ordinary Shares - Class A